IMMUNOVANT INC (IMVT)
Health Care · biotechnology · NASDAQ
Immunovant is a clinical-stage biotechnology company developing FcRn-inhibiting therapies to treat patients suffering from debilitating IgG-mediated autoimmune diseases.
What IMMUNOVANT INC does
Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases. Its primary product candidate is imeroprubart (IMVT-1402), a neonatal fragment crystallizable receptor (FcRn) inhibitor designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies. The company targets applications across several medical specialties including neurology, rheumatology, endocrinology, and dermatology.
Themes: autoimmune disease therapies, FcRn inhibitors, immunology drug development, IgG reduction therapies
Fundamentals
- Price$44.37 as of 2026-08-21 close
- Market cap$9.2B as of 2026-08-21
- 1-year return+199.0% 2025-08-21 close $14.84 → 2026-08-21 close $44.37
- P/En/a earnings data not available
- ROE-69.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.83 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How IMVT compares in its sector
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
IMVT is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
55.4 #454 of 1,704 scored · #87 of 240 in Health Care
Trend 78th: it is trading 13.0% above its 50-day average, the short-term trend line; momentum 64th: over the past 3 months this stock beat the market by 26.9 percentage points; weakest is setup 34th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 2% of it.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How IMMUNOVANT INC looks technically
IMMUNOVANT INC (IMVT) is trading 50.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 196 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 70, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 2.3% below its 52-week high (its highest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 50.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +50.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $39.27 | $39.27 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $29.53 | $29.53 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 36.78. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 196 trading days ago — a "golden cross", a bullish long-term signal | 196 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 22.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 70, neither overbought (above 70) nor oversold (below 30) | 69.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($37.98 to $45.42) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 85.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 8 trading days ago (its momentum flipped positive) | 8 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.42 | $45.42 |
|---|---|---|
| From the 52-week high | it is 2.3% below its 52-week high (its highest price of the past year) | -2.3% |
| Above the 52-week low | it is 206.6% above its 52-week low (its lowest price of the past year) | +206.6% |
| Below the 52-week high | it is 2.3% below its highest point of the past year | 2.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $53.75 (set on 2020-11-18) | $53.75 |
| Given back of the 52-week move | over the past year its closes ranged ($14.69 to $44.96), and it has given back essentially none of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $25.28 to $26.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.9% |
| From the all-time high | it is 17.5% below its all-time high | -17.4% |
| Nearest price level | it is trading 7.1% above a support level at $41.22 — a price it turned at twice since 2026-07-09, most recently on 2026-07-20. Since 2024-08-21 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -7.1% |
| All-time low | its lowest closing price on record is $3.15 (set on 2022-06-13) | $3.15 |
| Above the all-time low | it is 1310.8% above its all-time low | +1,311% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 59th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.52 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.52 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $36.71 and $45.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $36.71 – $41.06 – $45.42 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 9.8 daily ranges above its 200-day average price (50.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.83× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.9% since the prior reading | -0.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.1% |
|---|---|---|
| Open gap | it gapped 3.1% above the previous close 43 sessions ago and has not traded back through the level it left behind at 35.34 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +3.1% |
| Gap filled | a 2.2% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 9.9 percentage points (the stock gained 12.2% while the market gained 2.3%) | +9.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 26.9 percentage points (the stock gained 30.0% while the market gained 3.1%) | +26.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 55.7 percentage points (the stock gained 66.8% while the market gained 11.1%) | +55.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 178.5 percentage points (the stock gained 199.0% while the market gained 20.5%) | +178.5% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +17.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 42% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $31.15 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +42.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $42.48 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +4.4% |
Price levels it has turned at before
IMVT last closed at $44.37 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $41.22 | Support | 7.1% below the last close | turned there twice · 2026-07-09 to 2026-07-20 |
| $36.53 | Support | 17.7% below the last close | turned there twice · 2026-05-20 to 2026-08-03 |
| $30.19 | Support | 31.9% below the last close | turned there three times · 2026-04-23 to 2026-06-03 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $36.78.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · beating the market · Stretched far above its 200-day average (6+ daily ranges) · At the top of its 14-day range (stochastic above 80) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.63 mean, 1=Strong Buy…5=Strong Sell) — 16 analysts
- Mean price target$47.88 range $24.00 – $66.00; median $48.50
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for IMVT
- Consensus EPS estimate-$0.7338 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical-stage company with no commercial products, history of operating losses, and significant ongoing capital requirements.","Heavy reliance on the successful clinical development and regulatory approval of a single primary asset, IMVT-1402.","Dependence on third-party collaborations and potential risks associated with intellectual property licensing."]
What changed in the latest 10-Q
AI-assisted comparison of IMVT's 10-Q filed 2026-02-06 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-02-06) adds 'Immunovant, Inc.' in parentheses in Overview section opening: 'Immunovant, Inc. ("Immunovant," "we" or the "Company")' vs. older filing (2025-11-10) which states 'Immunovant is a clinical-stage immunology company'
- Removed:
- Older filing (2025-11-10) states 'across more than 20 indications currently being evaluated in clinical trials by multiple companies' - newer filing (2026-02-06) changes to 'across more than 20 indications that have been publicly announced for study by multiple companies'
- Reworded:
- Older filing (2025-11-10): 'have initiated and are currently enrolling studies in six indications' changed to newer filing (2026-02-06): 'have ongoing studies in six indications'
- Forward-Looking Statements section: older filing (2025-11-10) states 'Except as required by law' while newer filing (2026-02-06) states 'Except as required by applicable law'
- Notes:
- Both filings are truncated at the same point ('We initiated two potentia...' / 'We initiated two potentially registrational trial'), limiting full comparison of subsequent sections
Risk Factors
- Added:
- In newer filing (2026-02-06): Balance sheet dated December 31, 2025 added, showing cash and cash equivalents of $994,525 thousand and common stock shares outstanding of 203,316,885
- In newer filing (2026-02-06): Statement of Operations for nine months ended December 31, 2025 added, showing net loss of $357,750 thousand
- In newer filing (2026-02-06): Statement of Comprehensive Loss for nine months ended December 31, 2025 added
- In newer filing (2026-02-06): Stockholders' Equity statement extended to include quarter ended December 31, 2025, showing issuance of common stock upon underwritten offering of 26,200,000 shares for $543,608 thousand
- In newer filing (2026-02-06): Opening language added stating 'We make available free of charge on our website our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports...as soon as reasonably practicable'
- Removed:
- In older filing (2025-11-10): Balance sheet dated September 30, 2025 removed (replaced with December 31, 2025)
- In older filing (2025-11-10): Statement of Operations for six months ended September 30, 2025 removed (replaced with nine months ended December 31, 2025)
- In older filing (2025-11-10): Statement of Comprehensive Loss for six months ended September 30, 2025 removed (replaced with nine months ended December 31, 2025)
- In older filing (2025-11-10): Stockholders' Equity statement that ended at September 30, 2025 replaced with extended version through December 31, 2025
- In older filing (2025-11-10): Cash Flows statement for six months ended September 30, 2025 removed (document text truncated in newer filing)
- Reworded:
- Page numbering for Item 2, Item 3, Item 4, Item 5, and Item 6 changed from pages 30-31 in older filing to pages 32-33 in newer filing
- Opening paragraph in 'Where You Can Find More Information' section expanded in newer filing (2026-02-06) to include detailed description of website availability and investor communication methods; older filing (2025-11-10) begins directly with 'Investors and others should note...'
- Notes:
- The newer filing text appears truncated at the end of the Cash Flows statement, so full comparison of that section is not assessable
- Comparison focuses on the provided sections which are primarily financial statements and boilerplate text rather than Risk Factors content per se
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 24 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 24 sells ($12M) — 7 selling insiders
- Last 180 days0 buys · 31 sells ($13M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-24. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about IMVT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding IMVT as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 28,470,112
- Reported value $707,197,597
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
IMVT had 16,375,679 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
IMVT had 7.93% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 18.52 days to cover at the same settlement.
- Reported short interest (shares) 16,375,679
- Short interest (% of shares outstanding) 7.93%
- Prior settlement (shares) 17,758,956
- Reported change -7.79%
- Days to cover (reported) 18.52
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Argenx (ARGX)
- Alexion Pharmaceuticals (AstraZeneca) (AZN)
- UCB (UCBJY)
- Johnson & Johnson (JNJ)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare IMVT vs…
Frequently asked questions
What does IMMUNOVANT INC (IMVT) do?
Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases. Its primary product candidate is imeroprubart (IMVT-1402), a neonatal fragment crystallizable receptor (FcRn) inhibitor designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies. The company targets applications across several medical specialties including neurology, rheumatology, endocrinology, and dermatology.
What sector is IMMUNOVANT INC (IMVT) in?
IMMUNOVANT INC (IMVT) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are IMMUNOVANT INC's (IMVT) competitors?
Notable peers of IMMUNOVANT INC (IMVT) include Argenx, Alexion Pharmaceuticals (AstraZeneca), UCB, Johnson & Johnson and Amgen. This peer set is informational only — not financial advice.
Is IMMUNOVANT INC (IMVT) overbought or oversold right now?
IMMUNOVANT INC (IMVT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 70, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on IMVT come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.